Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share (the "Shares")
-
Shares outstanding
-
31,306,673
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
23,250,351
-
Shares change
-
-129,687
-
Total reported value, excl. options
-
$139,966,100
-
Value change
-
-$971,335
-
Number of buys
-
24
-
Number of sells
-
18
-
Price
-
$6.02
Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) as of Q4 2024
As of 31 Dec 2024 Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) had 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 23,250,351 shares of stock of the company.
Largest 10 holders included RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, Sands Capital Ventures, LLC, CITADEL ADVISORS LLC, BlackRock, Inc., WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, MARSHALL WACE, LLP, ACORN CAPITAL ADVISORS, LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This table shows 60 institutional shareholders of the security as of 31 Dec 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.